(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 July 2014 (17.07.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/108484 A2

(51) International Patent Classification:
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/EP2014/050344

(22) International Filing Date:
10 January 2014 (10.01.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
13151076.0 11 January 2013 (11.01.2013) EP

(71) Applicant *(for all designated States except US)*: **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacher Strasse 124, CH-4070 Basel (CH).

(71) Applicant *(for US only)*: **HOFFMANN-LA ROCHE INC.** [US/US]; 340 Kingsland Street, Nutley, New Jersey 07110 (US).

(72) Inventors: **BAUSS, Frieder**; Rottstrasse 11, 67141 Neuhofen (DE). **BOSSENMAIER, Birgit**; Horst-Wolfram-Geißler-Weg 10, 82229 Seefeld (DE). **FRIESS, Thomas**; St. Martin-Strasse 8a, 86911 Diessen-Dettenhofen (DE). **GERDES, Christian**; Sandfelsenstrasse 4, CH-8703 Erlenbach (CH). **HASMANN, Max**; Rudolf-Zenker-Strasse 10, 81377 Muenchen (DE). **THOMAS, Marlene**; Saalangerstraße 5, 82377 Penzberg (DE). **WEISSER, Martin**; Primel Strasse 1, 82377 Penzberg (DE).

(74) Agents: **JENNI, Wolfgang** et al.; Roche Diagnostics GmbH, Patent Department (LPP.....6164), P.O.Box 11 52, 82372 Penzberg (DE).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,

[Continued on next page]

(54) Title: COMBINATION THERAPY OF ANTI-HER3 ANTIBODIES

Fig. 7

(57) Abstract: The present invention relates to the combination therapy of anti-HER3 antibodies with certain anti-HER antibodies.



WO 2014/108484 A2

MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*